Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 531739 | NSE Symbol : | ISIN : INE509C01026 | Industry : Pharmaceuticals - Indian - Bulk Drugs |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
03-Feb-2025	14-Feb-2025	Quarterly Results	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter and Nine Months ended December 31 2024; 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Nine Months ended December 31 2024; 3. Other Business items. In just concluded Meeting of Board of Directors, the Board considered and approved the following items 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31, 2024 2. Limited Review Report from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31, 2024. 3. Resignation of Mr. Mohammed Khaleequr Rahman, Non-Excutive and Non-Independent Director of the Company 4. Other Business items We hereby submit that the Board Meeting commenced at 4.00 PM and concluded at 6.15 PM. The intimation is also being uploaded on the Company Website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same. (As Per Bse Announcement Dated on 14.02.2025)
05-Nov-2024	14-Nov-2024	Quarterly Results	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter and Half Year ended September 30 2024; 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Half-Year ended September 30 2024; 3. Reconstitution of the Audit Committee of the Company; 4. Reconstitution of the Nomination & Remuneration Committee of the Company; 5. Reconstitution of the Stakeholders Relationship Committee of the Company; 6. Other Business items. In just Concluded Meeting of Board of Directors the Board approved and considered the following items: 1. Unaudited Financial Statements for the Quarter and Half year ended September 30, 2024 2. Limited Review Reports from the Statutory Auditors 3. Reconstitution of Board Committees 4. Appointment of Chief Financial Officer 5. Other Items We hereby submit that the Board Meeting had commenced at 04.00 PM and concluded at 11.00 PM. The intimation is also uploaded at Company website: www.gennexlab.com We request you to take the above information on record and acknowledge receipt of the same. (As Per Bse Announcement Dated on 14.11.2024)
28-Aug-2024	06-Sep-2024	AGM	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2024 inter alia to consider and approve 1. To decide regarding the conduct of 39th AGM for the year ended March 31 2024; 2. To Consider and Appoint Scrutinizer of the 39th Annual General Meeting in case of Finalisation of the Date of AGM; 3. Any other business with permission of the Chairperson. In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Draft Directors''/ Board Report for the Financial Year March 31, 2024; 2. The 39th Annual General Meeting of the Company to be held on Monday, September 30, 2024 at 12:30 P.M.; 3. Secretarial Audit Report issued by Mr. Rakesh Kumar Gupta, Practicing Company Secretary, Kolkata; 4. Appointment of Ms. Ekta Goswami, Practicing Company Secretary, Kolkata as Scrutinizer for the AGM; 5. Book Closure Date in connection with 39th AGM between September 23, 2024 to September 30, 2024; 6. Appointment of Mr. Mohammed Khaleequr Rahman, as Additional Director (Non-Executive - Non Independent) of the Company. 7. Appointment of Mr. Rakesh Kumar Gupta, Practicing Company Secretary, Kolkata as a Secretarial Auditor for the Financial Year 2024-25. We hereby submit that the Board Meeting had commenced at 04:30 PM and concluded at 05:00 PM.
05-Aug-2024	14-Aug-2024	Quarterly Results	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve With reference to the above captioned subject matter we hereby inform you that the Meeting of Board of Directors of the Company will be held on Wednesday August 14 2024 at 04:00 PM at the Corporate Office of the Company inter-alia consider the following matters among other items of agenda: 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter ended June 30 2024; 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter ended June 30 2024; 3. Other Business items. Pursuant to SEBI (Prohibition of insider Trading) Regulations 2015 the closure of trading window will end after 48 hours after the results are made public. This intimation is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same. In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2024 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2024 (annexed here with); 3. Change in address of Corporate office of the Company from 3rd floor to 4th floor of the same premises i.e. New Address: Akash Ganga, 04th Floor, Plot#144, Srinagar Colony, Hyderabad - 500 073, Telangana State, India. 4. Acceptance of resignation of Mr. Laxmipat Baid, Chief Financial Officer of the Company. 5. Other Business items. We hereby submit that the Board Meeting had commenced at 04:00 PM and concluded at 05:00 PM (As per BSE Announcement Dated on 14/08/2024)
21-May-2024	30-May-2024	Accounts	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve 1. Audited Financial Statements (Standalone and Consolidated) for the Quarter and Year ended March 31 2024; 2. Independent Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Year ended March 31 2024; 3. Other Business items. Pursuant to SEBI (Prohibition of insider Trading) Regulations 2015 the closure of trading window will end after 48 hours after the results are made public. This intimation is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same. In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Audited Standalone and Consolidated Financial results for the Quarter ended and Year ended March 31, 2024. 2. Auditor''s Report on audited Standalone and Consolidated Financial Statements for the Quarter and Year ended March 31, 2024, issued on dated May 30, 2024 along with the Statement on Impact of Audit Qualification (Standalone and Consolidated) are attached herewith - Annexure I; We hereby submit that the Board Meeting had commenced at 4:00 pm and concluded at 7:30 pm. This intimation is also uploaded on the Company website www.gennexlab.com We request you to take the above information on record and acknowledge the receipt of the same (As per BSE Announcement Dated on 30/05/2024)
01-Feb-2024	14-Feb-2024	Quarterly Results	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter and Nine Months ended December 31 2023; 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Nine Months ended December 31 2023; 3. Other Business items. Pursuant to SEBI (Prohibition of insider Trading) Regulations 2015 the closure of trading window will end after 48 hours after the results are made public. This intimation is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same. With reference to above mentioned subject matter, this is to inform you that Mr. Tiruvarur Muralidharan Gopalakrishnan, Whole time Director has tendered his resignation from the Board as Director of the Company due to personal reasons of age and health. However, he will continue with the Company looking after Operations and R&D activities including new product development. The resignation letter shall be placed before the Board of the Directors in the upcoming Board meeting to be held on February 14, 2024 for its consideration and formal acceptance in accordance with the aforementioned regulation. The intimation is also being uploaded on the Company'' website: www.gennexlab.com We request you to take the above information on record and acknowledge receipt of the same. In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31, 2023 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31, 2023 (annexed here with); 3. Acceptance of Resignation of Mr. Tiruvarur Muralidharan Gopalakrishnan, Whole time Director of the Company; 4. Appointment of Dr. S.CH. DHARMA RAO, as Additional Director (Non-Executive - Non Independent Director) of the Company. We hereby submit that the Board Meeting had commenced at 04:00 PM and concluded at 05:00 PM. This intimation is also uploaded on the Company website: www.gennexlab.com We request you to take the above information on record and acknowledge the receipt of the same. In just concluded meeting of Board of Directors, the Board approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statement for the Quarter and Nine months ended December 31, 2023 2.Limited Review Reports from the Statutory Auditors on unaudited (Standalone and Consolidated) Financial Statement for the Quarter and Nine months ended December 31, 2023 3. Acceptance of resignation of Mr. Tiruvarur Muralidharan Gopalakrishnan, Whole time Director of the Company 4. Appointment of Dr, S.CH. Dharma Rao, as Additional Director (Non-Executive - Non-Independent Director) of the Company. We hereby submit that the Board Meeting had commenced at 4.00 PM and concluded at 5.00 PM. This intimation is also uploaded on the Company website: www.gennexlab.com We request you to take the above information on record and acknowledge the receipt. (As per BSE Announcement Dated on 14/02/2024)
27-Jan-2024	27-Jan-2024	Preferential Issue	Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with Schedule III thereto, and in furtherance to our intimation dated 20/11/2023, 29/11/2023, and Board meeting outcome filed on 02/12/2023, we wish to inform you that Board of Directors of the Company, at its meeting held today, on 27/01/2024 has considered and approved the following: 1. Allotment of 5,00,00,000 equity shares of the Company having face value of Re. 1/- each at a price of Rs. 14.75/- aggregating to Rs. 73,75,00,000 on preferential basis to specified persons. 2. Allotment of 1,55,00,000 share warrants of the Company at a price of Rs. 14.75 each (warrant subscription price Rs. 3.69/- and the warrant exercise price Rs. 11.06/- per warrant) aggregating to Rs. 22,86,25,000 to the member of promoter group on a preferential basis. The meeting commenced at 2.00 PM and concluded at 2.30 PM. We request you to take the above information on record and acknowledge receipt of the same.
20-Nov-2023	02-Dec-2023	Preferential Issue	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/12/2023 inter alia to consider and approve We hereby inform you that the Board Meeting will be held on 02/12/2023 at 02.00 P.M. at its Corporate Office at Akash Ganga Plot 144 Srinagar Colony Hyderabad 500073 inter alia to consider the following matters among other items of agenda: 1. To consider and approve the proposal for an increase in the authorized share capital of the Company from Rs.20 Crores to Rs.25 Crores subject to the necessary approvals. 2.To consider and approve the Preferential Issue of Equity Shares to specific individuals and entities subject to obtaining the requisite approvals from the shareholders and regulatory authorities. 3. To discuss and decide on any other matter that the Board may deem fit and necessary. Please note that as per the Companys Code of Conduct for Prohibition of Insider Trading the Trading Window shall remain closed for all Designated Persons from 20/11/2023 to 02/12/2023 (both days inclusive). This intimation is also being uploaded on the Company website: www.gennexlab.com. GENNEX LABORATORIES LIMITED has informed BSE about Board Meeting to be held on 02 Dec 2023 to consider Increase in authorised capital / Fund raising / Other business. GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/12/2023 ,inter alia, to consider and approve This intimation is revision of the Board meeting intimation given on November 20, 2023. (As Per BSE Announcement Dated on 29/11/2023) Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015 in furtherance to our intimation dated 20/11/2023 and 29/11/2023, we wish to inform you that Board of Directors of the Company, at its meeting held today, on 02/12/2023 has considered and approved the following: 1. To increase the authorised share capital of the Company from Rs. 20 Crore to Rs. 25 Crore and consequential alteration in Clause V of the MOA and Clause 4(i) of the AOA of the Company subject to approval of the shareholders of the Company. 2. Issuance of upto 5,00,00,000 equity shares of the Company having face value of Rs. 1/- each on preferential basis to specified persons 3. Issuance of upto 1,55,00,000 share warrants of the Company to the promoters and members of promoter group on a preferential basis 4. Calling of Extraordinary General Meeting 5. Book Closure for ensuing EGM and record date/ cut-off date for e-voting. The meeting commenced at 2:00 pm and concluded at 4:00 pm. (As Per BSE Announcement Dated on 02.12.2023) Board has considered and approved the following: 1. Increase in authorised share capital To increase the authorised share capital of the Company from Rs. 20 Crore (Rupees Twenty Crore) divided into 20 Crore equity shares of face value Re. 1/- each to Rs. 25 Crore (Rupees Twenty-Five Crore) divided into 25 Crore equity shares of face value Re. 1/- each and consequential alteration in Clause V of the Memorandum of Association and Clause 4(i) of the Articles of Association of the Company subject to approval of the shareholders of the Company. 2. Issuance of upto 5,00,00,000 equity shares of the Company having face value of Rs. 1/- each on preferential basis to specified persons To issue upto 5,00,00,000 (Five Crores) equity shares of the Company having face value of Re. 1/- each (Rupee One only) to non-promoters/ public category of shareholders at a price of Rs. 14.75/- each (Rupees Fourteen and Seventy-Five Paise only), on the basis of the valuation report obtained from an independent registered valuer, aggregating to upto Rs. 73,75,00,000/- (Rupees Seventy-Three Crore and Seventy-Five Lacs only) on a preferential basis in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018 ('SEBI ICDR Regulations'), as amended, and other applicable laws, subject to the approval of regulatory/ statutory authorities and the shareholders of the Company. (As Per BSE Bulletin Dated on 04.12.2023)
03-Nov-2023	14-Nov-2023	Half Yearly Results	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Half Year ended September 30 2023; 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Half-Year ended September 30 2023; 3. Any other business with permission of the Chairperson. This intimation is also being uploaded on the Company website: www.gennexlab.com. In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30, 2023 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30, 2023 (annexed here with). We hereby submit that the Board Meeting had commenced at 04:30 PM and concluded at 05:00 PM. This intimation is also uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. (As Per BSE Announcement Dated on 14.11.2023) Pursuant to Regulation 47 of SEBI (LODR), 2015, please find enclosed herewith Newspaper Publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30, 2023 announced by the Board of Directors in its meeting held on Tuesday November, 14, 2023. Financial results had been published in both Business Standard (English) and Saksham (Telugu-Local) on Thursday November 16, 2023. We request you to take the above information on record and acknowledge receipt of the same. (As Per BSE Announcement Dated on 16.11.2023)
29-Aug-2023	06-Sep-2023	AGM	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2023 inter alia to consider and approve With reference to the above captioned subject matter pursuant to the referred regulations of SEBI (LODR) Regulations 2015 mentioned above we hereby inform you that the Meeting of Board of Directors of the Company will be held on Wednesday September 06 2023 at 04.30 P.M. at its Corporate Office at Akash Ganga Plot 144 Srinagar Colony Hyderabad Telangana 500073 inter alia to consider the following matters among other items of agenda: 1. To decide regarding the conduct of 38th AGM for the year ended March 31 2023; 2. To Consider and Appoint Scrutinizer of the 38th Annual General Meeting in case of Finalisation of the Date of AGM; 3. Any other business with permission of the Chairperson. This intimation is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same. In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Draft Directors''/ Board Report for the Financial Year March 31, 2023; 2. The 38th Annual General Meeting of the Company to be held on Saturday, September 30, 2023 at 12:30 P.M.; 3. Secretarial Audit Report issued by Mr. Rakesh Kumar Gupta, Practicing Company Secretary, Kolkata; 4. Appointment of Ms. Ekta Goswami, Practicing Company Secretary, Kolkata as Scrutinizer for the AGM; 5. Book Closure Date in connection with 38th AGM between September 23, 2023 to September 30, 2023; 6. Appointment of Mr. Rakesh Kumar Gupta, Practicing Company Secretary, Kolkata as a Secretarial Auditor for the Financial Year 2023-24. We hereby submit that the Board Meeting had commenced at 04:30 PM and concluded at 05:00 PM. This intimation is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same. (As Per BSE Announcement dated on 06.09.2023)
03-Aug-2023	14-Aug-2023	Quarterly Results	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve With reference to the above captioned subject matter pursuant to the referred regulations of SEBI (LODR) Regulations 2015 mentioned above we hereby inform you that the Meeting of Board of Directors of the Company will be held on Monday August 14 2023 at 04.30 P.M. at its Corporate Office at Akash Ganga Plot 144 Srinagar Colony Hyderabad Telangana 500073 inter alia to consider the following matters: 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter Ended June 30 2023; 2. Consider the Limited Review Reports of the Statutory Auditors on Standalone and Consolidated unaudited Financial Statements for the Quarter Ended June 30 2023; 3. Any other business with permission of the Chairperson. This intimation is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same. In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2023 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2023 (annexed here with). We hereby submit that the Board Meeting had commenced at 04:30 PM and concluded at 06:00 PM. This intimation is also uploaded on the Company website: www.gennexlab.com We request you to take the above information on record and acknowledge the receipt of the same. Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended 30.06.2023 along with Limited Review Reports from the Statutory Auditors for that period as approved and considered by the Board of Directors in their meeting held on 14.08.2023 (As Per BSE Announcement Dated on 14.08.2023) Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith Newspaper Publication of Unaudited (Standalone and Consolidated) Financial results for the First Quarter ended June 30, 2023 announced by the Board of Directors in its meeting held on Monday. August 14, 2023. Financial Results had been published in both Business Standard (English) and Saksham (Telugu-Local) on Thursday August 17, 2023. (As Per BSE Announcement dated on 17.08.2023)
20-May-2023	30-May-2023	Accounts	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve With reference to the above captioned subject matter pursuant to the referred regulations of SEBI (LODR) Regulations 2015 mentioned above we hereby inform you that the Meeting of Board of Directors of the Company will be held on Tuesday May 30 2023 at 04.30 P.M. at its Corporate Office at Akash Ganga Plot 144 Srinagar Colony Hyderabad Telangana 500073 inter alia to consider the following matters: 1. Consider and adopt the Audited Financial Statements (Standalone and Consolidated) for the 4th Quarter and Year Ended March 31 2023; 2. Consider the Limited Review Reports of the Statutory Auditors on Standalone and Consolidated Audited Financial Statements for the 4th Quarter and Year Ended March 31 2023; 3. Any other business with permission of the Chairperson. This intimation is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same. In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the quarter ended & Year Ended March 31, 2023; 2. Auditor''s Report on audited Standalone & Consolidated Financial Statements for the Quarter and Year ended March 31, 2023, issued on dated May 30, 2023 along with the Statement on Impact of Audit Qualification (Standalone & Consolidated) are attached herewith - Annexure I; We request you to take the above information on record and acknowledge the receipt of the same. (As per BSE Announcement Dated on 31/05/2023) This has reference to your email dated 01.06.2023 regarding Additional Details Required for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015. In continuation to our intimation dated 30.05.2023 with reference to the 'Outcome of the Board Meeting' regarding Audited Standalone and Consolidated Financial Results for the 4th quarter and year ended 31.03.2023, please note that the said Board Meeting had commenced at 16.30 p.m. on 30.05.2023 and concluded at 2.10 a.m. on 31.05.2023. This is for your kind information and records. (As Per BSE Announcement Dated on 01.06.2023)
12-Apr-2023	20-Apr-2023	Change in Other Executives	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/04/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 Notice is hereby given that a Meeting of the Board of Directors of the Company is scheduled to be held on Thursday April 20 2023 at 11:30 A.M. at its Corporate Office at Akash Ganga Plot 144 Srinagar Colony Hyderabad Telangana 500073 inter alia: 1. To Consider and Appoint Mr. Dinesh Kumar Kejriwal as a Company Secretary & Compliance Officer of the Company. 2. To Consider and Approve the appointment of Mr. Arihant Baid act as Managing Director in the Deccan Remedies Limited which is a Subsidiary of Gennex Laboratories Limited. 3. Any other business with permission of the Chairperson. In just concluded meeting of the board directors of the company, the board has considered and approve: 1. Appoint Mr. Dinesh Kumar Kejriwal as a Company Secretary & Compliance Officer of the Company. 2. Propose to Appoint Mr. Arihant Baid to act as Managing Director in the Deccan Remedies Limited, which is a Subsidiary of Gennex Laboratories Limited. We hereby submit that the Board Meeting starts at 11:30 A.M. and concluded at 2:30 PM for your information. This intimation is also uploaded on the Company website: www.gennexlab.com We request you to take the above information on record and acknowledge the receipt of the same. (As Per BSE Announcement Dated on 20/04/2023)
07-Feb-2023	14-Feb-2023	Quarterly Results	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve With reference to the above-captioned subject matter we hereby inform you that the Meeting of the Board of Directors of the Company will be held on Tuesday February 14 2023 at 04:00 PM at the Corporate Office of the Company inter-alia consider the following matters among other items of agenda: 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter and Nine Months ended December 31 2022; 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Nine Months ended December 31 2022; 3. Other Business items. Pursuant to SEBI (Prohibition of insider Trading) Regulations 2015 the closure of trading window will end after 48 hours after the results are made public. This intimation is also uploaded on the Company website: www.gennexlab.com. We request you take note of the above information on record and acknowledge the receipt of the same. In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine Months ended December 31, 2022 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine Months ended December 31, 2022 (annexed herewith); 3. Acceptance of Resignation of Mr. Rajesh Vankadara, as company secretary & Compliance officer of the Company. This intimation is also uploaded in the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine Months ended December 31, 2022 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine Months ended December 31, 2022 (annexed herewith); 3. Acceptance of Resignation of Mr. Rajesh Vankadara, as company secretary & Compliance officer of the Company. This intimation is also uploaded in the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. With reference to your email towards the additional details required for filed under Regulation 30 of SEBI (LODR) Regulations, 2015 of Unaudited (Standalone & Consolidated) Financial Results For The Quarter And Nine Months Ended December 31, 2022 Along With The Limited Review Report Of The Statutory Auditor. We hereby submit the Boarding Meeting starts at 04:00 PM as informed in the Board Meeting intimation and it concluded at 05:15 PM for your information. We hereby request you that Board Meeting concluding timing was missed and it was an unintentional act, kindly consider this one and request you not to penalize us. We request you to take the above information on record and acknowledge the receipt of the same. (As Per BSE Announcement Dated on 14.02.2023)
04-Nov-2022	14-Nov-2022	Quarterly Results	GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve With reference to the above captioned subject matter pursuant to the referred regulations of SEBI (LODR) Regulations 2015 mentioned above we hereby inform you that the Meeting of the Board of Directors of the Company scheduled on Monday November 14 2022 at the Corporate Office of the Company inter-alia to consider the following matters: 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Half Year ended September 30 2022; 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Half-Year ended September 30 2022; 3. Other Business items. This intimation is also being uploaded in the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half Year ended September 30, 2022 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half Year ended September 30, 2022 (annexed herewith). This intimation is also uploaded in the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. (As Per BSE Announcement Dated on 14.11.2022) Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed herewith Newspaper Publication on Unaudited (Standalone & Consolidated) Financial results for the Quarter and Half Year ended September 30, 2022 announced by the Board of Directors in their meeting held on November 14, 2022. Financial results had been published in both Business Standard and Andhra Prabha on November 16, 2022. We request you to take the above information on record and acknowledge the receipt of the same. (As Per BSE Announcement Dated on 16/11/2022)

1 2 3

LOGIN HERE

Gennex Laboratories Ltd

Board Meeting